

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 018733/0967		SERIAL 09/5	
<b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)				APPLICANT David M. GOLDENBERG et al.			
				FILING DATE June 9, 2000		GROUP ART UNIT 1645 1644	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
JNR	A1	5,686,072	11/11/97	Uhr et al.	424	183.4	
JNR	A2	5,795,967	8/18/98	Aggarwal et al.	530	388.23	

FOREIGN PATENT DOCUMENTS								
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
						YES	NO	
JNR	A3	91/13974	WIPO					
JNR	A4	94/27638	WIPO					
JNR	A5	99/54440	WIPO					


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
JNR	A6	Todd D. Levine et al., "IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab.", Neurology, vol. 52, No. 8, pp. 1701-1704, May 12, 1999, XP-000942610
JNR	A7	A. Protheroe et al., "Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma.", Rheumatology, vol. 38, No. 11, pp. 1150-1152, November, 1999, XP-000942661
JNR	A8	Zhengxing Qu et al., "Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates.", Journal of Immunological Methods, vol. 213, No. 2, pp. 131-144, April 15, 1998, XP-0002103672
JNR	A9	W. Rowan et al., "Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B-and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.", Immunology, vol. 95, No. 3, pp. 427-436, November, 1998, XP-000942636
JNR	A10	Rhona Stein et al., "Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2.", Cancer Immunology Immunotherapy, vol. 37, No. 5, pp. 293-298, 1993, XP-002070322
JNR	A11	Stamatios Theocharis et al., "Characterization of in Vivo Mutated T Cell Clones form Patients with Systemic Lupus Erythematosus <sup>1</sup> .", Clinical Immunology and Immunopathology, vol. 74, No. 2, pp. 135-142, February, 1995, XP-000942609

EXAMINER 	DATE CONSIDERED 9/3/02
--------------	---------------------------

\* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 018733/0967		SERIAL NO. 0970	
INFORMATION DISCLOSURE CITATION				APPLICANT David M. GOLDENBERG and Hans J. HANSEN			
				FILING DATE June 9, 2000		GROUP ART UNIT 1645 K44	
Date Submitted to PTO: November 16, 2000							
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME		SUB- CLASS	FILING DATE IF APPROPRIATE
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
JWZ	A1	Pawlak- Byczkowska, et al.		Two New Monoclonal Antibodies, EPB-1 and EPB-2, Reactive With Human Lymphoma; CANCER RESEARCH: 49, No. 16, 4568-4577, (1989)			
DM	A2	Shih, et al.		Internalization and Intracellular Processing Of An Anti-B-Cell Lymphoma Monoclonal Antibody, LL2; INT. J. CANCER: 56, 538-545, (1994)			
DR	A3	Leung, et al.		Chimerization of LL2, a Rapidly Internalizing Antibody Specific For B Cell Lymphoma; HYBRIDOMA: 13, No. 6, 469-476, (1994)			
JWZ	A4	Ghetie, et al.		Evaluation of Ricin A Chain-Containing Immunotoxins Directed Against CD19 and CD22 Antigens On Normal and Malignant Human B-Cells As Potential Reagents For In Vivo Therapy; CANCER RESEARCH: 48, No. 9, 2313-2634, (1988)			
JWZ	A5	Hekman, et al.		Initial Experience With Treatment Of Human B Cell Lymphoma With Anti-CD19 Monoclonal Antibody; CANCER IMMUNOLOGY IMMUNOTHERAPY: 32, 364-372, (1991)			
JWZ	A6	Kaminski, et al.		Radioimmunotherapy of B-Cell Lymphoma With [ <sup>131</sup> I] Anti-B1 (Anti-CD20) Antibody; THE NEW ENGLAND JOURNAL OF MEDICINE: 329, No. 7, 459-465, (1993)			
JWZ	A7	Press, et al.		Radiolabeled-Antibody Therapy Of B-Cell Lymphoma With Autologous Bone Marrow Support; THE NEW ENGLAND JOURNAL OF MEDICINE: 329, No. 17, 1219-1224, (1993)			
DM	A8	Maloney, et al.		Phase I Clinical Trial Using Escalating Single-Dose Infusion Of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) In Patients With Recurrent B-Cell Lymphoma; JOURNAL OF THE AMERICAN SOCIETY OF HEMATOLOGY: 84, No. 8, 2457-2466, (1994)			
DM	A9	Press, et al.		Phase II Trial Of [ <sup>131</sup> I]-B1 (anti-CD20) Antibody Therapy With Autologous Stem Cell Transplantation For Relapsed B Cell Lymphomas; THE LANCET: 346, No. 8971, 336-340, (1995)			
DM	A10	Longo		Immunotherapy For Non-Hodgkin's Lymphoma; CURRENT OPINION IN ONCOLOGY: 8, No. 5, 353-359, (1996)			
EXAMINER				DATE CONSIDERED			
				9/3/02			
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.</p>							

**Complete if Known**

<b>Application Number</b>	09/590,284
<b>Filing Date</b>	06/09/2000
<b>First Named Inventor</b>	David M. Goldenberg
Group Art Unit	1644
Examiner Name	J. Roark
Attorney Docket Number	018733-0967

Sheet	1	of	1
-------	---	----	---

[illegible][illegible]

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
me	C1	HESS et al., "Specificity of Effector T Lymphocytes in Autologous Graft-Versus-Host Disease: Role of the Major Histocompatibility Complex Class II Invariant Chain Peptide", Blood, Mar. 1997, pp. 2203-2209, Vol. 89, No. 6	

9/3/02

1 Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the designation page.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.